Australia Australian biotech firm Vaxxas set for clinical trials of needle-free vaccine patches
Vaccine mandate challenge expands to more than 100 plaintiffs
A legal challenge to Victoria's COVID-19 vaccine mandate launched by a teacher and her husband has been dramatically expanded to include more than 100 plaintiffs from a broad range of occupations, including an employee of CSL which manufactures the vaccine.Revised documents filed in the Supreme Court of Victoria accuse Chief Health Officer Brett Sutton and other senior health bureaucrats of breaching the state's Human Rights Charter when they imposed vaccine mandates across several industries, including health, education and construction.
Brisbane-based biotechnology company Vaxxas is set to launch clinical trials delivering a COVID-19 vaccine with needle-free patches from mid-next year.
The company says the technology could boost Australia’s future vaccination rollout.
The clinical trials follow successful animal studies conducted by the University of Queensland in partnership with Vaxxas.
Under the testing, the patches were used to inoculate mice with the Hexapro vaccine, developed by the University of Texas, which successfully protected them from the virus.
Vaxxas head of medical device and process engineering Michael Junger told ABC Radio Brisbane the company was planning to conduct the human trials from mid next year, hopefully in Australia, and the technology had the potential for self-administration.
Pfizer’s clinical data puts the US one step closer to a Covid-19 vaccine for younger kids
A Covid-19 vaccine for children ages 5 to 11 could be authorized by early November.Pfizer also announced on Friday that the vaccine is more than 90 percent effective at protecting school-age children from serious illness or hospitalization from Covid-19, similar to the level of protection it provides in adults.
"COVID-19 is not going away, it will be with us for a long time. It’s not just about the vaccine, it’s about the administration of it," he said.
"If there’s a future pandemic, the last thing you want to do is rock up to a vaccination centre and line up with thousands of people to get a vaccine, so that leaves the door open to self administration."
So how does it work?
University of Queensland research, published in a peer-reviewed journal today, showed the vaccine patches produced a stronger and faster immune response than needles and syringes.
The technology, a "high-density microarray patch" has thousands of vaccine-coated microprojections that are applied to the skin for a few seconds to efficiently deliver the vaccine to the immune cells immediately below the skin surface.
Aussie scientist forced to crowd fund homegrown Covid vaccine
An Australian scientist who has developed an alternative 'synthetic protein' vaccine against Covid-19 has been forced to go hand-in-cap to try and fund its approval in Australia. Professor Nikolai Petrovaky has already raised more than $70,000 since listing his vaccine on GoFundMe last week. The Adelaide vaccine scientist, from Australian biotechnology company Vaxine, claims Covax-19 is the first synthetic protein vaccine against Covid-19 to receive market authorisation, after showing strong protection against the Delta virus variant in a Phase 3 clinical trial in 16,876 subjects in the Middle East.
Mr Junger told ABC Radio Brisbane.
"There is a sensation because we have to apply the patch at speed to breach the skin with such a dense array," he said.
Dr Muller said delivering the vaccine like this enhanced its effectiveness.
"That's where there is a high density of immune cells, so you're placing the vaccine where the cells can really process it," he said.
"You get a better quality of immune response compared with using a syringe."
Dr Muller said having the research published was a milestone in the process for the technology, and if the clinical trials were successful, it could "dramatically assist" the global vaccine rollout "for billions of vulnerable people".
"We have really promising pre-clinical data and we've been able to show promise against variants of concern — we've had promising antibodies against alpha and beta variants," Dr Muller said.
When is the Novavax COVID-19 vaccine coming to Australia, and how does it work?
When is the Novavax COVID vaccine coming to Australia, and how does it work? Here's what we know.The vaccines had been slated to arrive mid-year, but manufacturing delays and supply shortages have slowed the company's progress.
"We've shown this vaccine, when dry-coated on a patch, is stable for at least 30 days at 25 degrees Celsius and one week at 40 degrees, so it doesn't have the cold-chain requirements of some of the current options."
The device is already involved in many clinical trials, including.
'Revolution' for children, needle phobic
Dr Lara Herrero, an infectious diseases expert at Griffith University, said this patch technology was "quite revolutionary" for worldwide vaccine delivery in general, because it was not invasive and it did not require cold storage.
"I think it's critical for Australia to be on top of all new technologies and scientific advancements protecting not just Australians but the world," she said.
"I think time will tell whether or not this technology provides a more robust and specific immune response for SARS-CoV-2 but there are viruses naturally transmitted through breaks in skin that this technology — it's almost certain this is the best for."
A spokesperson from the Therapeutic Goods Association said in order for a new vaccine to be provisionally approved, a sponsor was required to submit a comprehensive dossier with clinical and scientific data supporting the safety, efficacy and quality of the product.
"This would typically include data from large well-conducted clinical trials in addition to other information," the spokesperson said.
The research is published in Sciences Advances Journal today.
Professor reveals he wouldn't give his children the Covid vaccine yet .
On Monday the US granted emergency approval for the Pfizer vaccine for children aged five to 11 after a study of 3,100 kids found it was safe.On Tuesday the US approved the Pfizer vaccine for children aged five to 11 after a study of 3,100 kids detected no serious side effects and found it was 90.7 per cent effective in preventing Covid-19 infection.